Cargando…
miR-34c-3p acts as a tumor suppressor gene in osteosarcoma by targeting MARCKS
Previous studies have demonstrated that microRNA (miR)-34c-3p is important in human cancer progression. However, the function of miR-34c-3p in osteosarcoma (OS) remains to be elucidated. In the present study, miR-34c-3p level was measured by reverse transcription-quantitative polymerase chain reacti...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367338/ https://www.ncbi.nlm.nih.gov/pubmed/28075441 http://dx.doi.org/10.3892/mmr.2017.6108 |
Sumario: | Previous studies have demonstrated that microRNA (miR)-34c-3p is important in human cancer progression. However, the function of miR-34c-3p in osteosarcoma (OS) remains to be elucidated. In the present study, miR-34c-3p level was measured by reverse transcription-quantitative polymerase chain reaction in OS tissues and the associated prognostic value for overall survival was determined. The function of miR-34c-3p was examined in vitro and in vivo. A luciferase reporter assay was used to identify the targets of miR-34c-3p. The results of the present study revealed that miR-34c-3p was downregulated in OS tissues and cell lines, and decreased levels of miR-34c-3p were associated with a high mortality rate in patients with OS. Furthermore, restoration of miR-34c-3p expression reduced cell growth in vitro and suppressed tumorigenesis in vivo. Conversely, inhibition of miR-34c-3p stimulated OS cell growth in vitro and in vivo. Myristoylated alanine-rich protein kinase C substrate (MARCKS) was identified as a direct target of miR-34c-3p and its overexpression partly reversed the suppressive effects of miR-34c-3p. Furthermore, MARCKS was revealed to be upregulated and inversely correlated with miR-34c-3p levels in OS tissues. These data suggested that miR-34c-3p acts as a tumor suppressor via regulation of MARCKS expression in OS progression and miR-34c-3p may be a promising therapeutic target for this type of cancer. |
---|